Wick M J, Dong L Q, Riojas R A, Ramos F J, Liu F
Departments of Pharmacology and Biochemistry, The University of Texas Health Science Center, San Antonio, Texas 78229, USA.
J Biol Chem. 2000 Dec 22;275(51):40400-6. doi: 10.1074/jbc.M003937200.
Phosphorylation of Thr(308) in the activation loop and Ser(473) at the carboxyl terminus is essential for protein kinase B (PKB/Akt) activation. However, the biochemical mechanism of the phosphorylation remains to be characterized. Here we show that expression of a constitutively active mutant of mouse 3-phosphoinositide-dependent protein kinase-1 (PDK1(A280V)) in Chinese hamster ovary cells overexpressing the insulin receptor was sufficient to induce PKB phosphorylation at Thr(308) to approximately the same extent as insulin stimulation. Phosphorylation of PKB by PDK1(A280V) was not affected by treatment of cells with inhibitors of phosphatidylinositol 3-kinase or by deletion of the pleckstrin homology (PH) domain of PKB. C(2)-ceramide, a cell-permeable, indirect inhibitor of PKB phosphorylation, did not inhibit PDK1(A280V)-catalyzed PKB phosphorylation in cells and had no effect on PDK1 activity in vitro. On the other hand, co-expression of full-length protein kinase C-related kinase-1 (PRK1/PKN) or 2 (PRK2) inhibited PDK1(A280V)-mediated PKB phosphorylation. Replacing alanine at position 280 with valine or deletion of the PH domain enhanced PDK1 autophosphorylation in vitro. However, deletion of the PH domain of PDK1(A280V) significantly reduced PDK1(A280V)-mediated phosphorylation of PKB in cells. In resting cells, PDK1(A280V) localized in the cytosol and at the plasma membrane. However, PDK1(A280V) lacking the PH domain localized predominantly in the cytosol. Taken together, our findings suggest that the wild-type PDK1 may not be constitutively active in cells. In addition, activation of PDK1 is sufficient to phosphorylate PKB at Thr(308) in the cytosol. Furthermore, the PH domain of PDK1 may play both positive and negative roles in regulating the in vivo function of the enzyme. Finally, unlike the carboxyl-terminal fragment of PRK2, which has been shown to bind PDK1 and allow the enzyme to phosphorylate PKB at both Thr(308) and Ser(473), full-length PRK2 and its related kinase PRK1/PKN may both play negative roles in PKB-mediated downstream biological events.
蛋白激酶B(PKB/Akt)激活过程中,激活环上的苏氨酸(Thr)308和羧基末端的丝氨酸(Ser)473磷酸化至关重要。然而,这种磷酸化的生化机制仍有待阐明。在此我们发现,在中国仓鼠卵巢细胞中过表达胰岛素受体时,表达组成型活性突变体小鼠3-磷酸肌醇依赖性蛋白激酶-1(PDK1(A280V))足以诱导PKB在Thr(308)处的磷酸化,其程度与胰岛素刺激大致相同。用磷脂酰肌醇3-激酶抑制剂处理细胞或缺失PKB的普列克底物蛋白同源(PH)结构域,均不影响PDK1(A280V)对PKB的磷酸化。细胞可渗透的间接PKB磷酸化抑制剂C(2)-神经酰胺,并不抑制细胞中PDK1(A280V)催化的PKB磷酸化,且对体外PDK1活性无影响。另一方面,共表达全长蛋白激酶C相关激酶-1(PRK1/PKN)或2(PRK2)可抑制PDK1(A280V)介导的PKB磷酸化。将280位的丙氨酸替换为缬氨酸或缺失PH结构域可增强体外PDK1的自身磷酸化。然而,缺失PDK1(A280V)的PH结构域可显著降低细胞中PDK1(A280V)介导的PKB磷酸化。在静息细胞中,PDK1(A280V)定位于胞质溶胶和质膜。然而,缺失PH结构域的PDK1(A280V)主要定位于胞质溶胶。综上所述,我们的研究结果表明野生型PDK1在细胞中可能不是组成型活性的。此外,PDK1的激活足以使胞质溶胶中的PKB在Thr(308)处磷酸化。此外,PDK1的PH结构域在调节该酶的体内功能中可能起正负两方面作用。最后,与已证明可结合PDK1并使该酶在Thr(308)和Ser(473)处均磷酸化PKB的PRK2羧基末端片段不同,全长PRK2及其相关激酶PRK1/PKN在PKB介导的下游生物学事件中可能均起负性作用。